Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 10/2008

01-10-2008 | Brief Report

Stability of varicella-zoster virus open reading frame 63

Published in: Archives of Virology | Issue 10/2008

Login to get access

Abstract

The stability of varicella-zoster virus (VZV) open reading frame (ORF) 63 was analyzed by sequential passage of a virus strain in cell culture. VZV was propagated in culture for 1,206 passages. ORF63 from six passages (18, 220, 516, 730, 1060, and 1,206) was selected and sequenced. Among the six passages, only passage 1,206 showed point mutations at three locations: 551, 618 and 661. In addition, western blot analysis with anti-ORF63 monoclonal antibodies showed no discernable difference in the size of the ORF63 gene product from passage 18 and that from passage 1,206. These results indicate the stability of VZV ORF63 gene in culture over 1,206 passages.
Literature
1.
Cohen JI, Cox E, Pesnicak L, Srinivas S, Krogmann T (2004) The varicella-zoster virus ORF63 latency-associated protein is critical for establishment of latency. J Virol 78:11833–11840PubMedCrossRef
2.
Cohen JI, Krogmann T, Bontems S, Sadzot-Delvaux C, Pensnicak L (2005) Regions of the varicella-zoster virus open reading fame 63 latency-associated protein important for replication in vitro are also critical for efficient establishment of latency. J Virol 79:5069–5077PubMedCrossRef
3.
Cohrs RJ, Randall J, Smith J, Gilden DH, Dabrowski C, van Der Keyl H, Tal-Singer R (2000) Analysia of individual human trigeminal ganglia for latent herpes simplex virus type I and varicella-zoster virus nucleic acids using real time PCR. J Virol 74:11464–11471PubMedCrossRef
4.
Cohrs RJ, Barbour M, Gilden DH (1996) Varicella-zoster virus (VZV) Transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol 70:2789–2796PubMed
5.
Cohrs RJ, Gilden DH (2007) Prevalence and abundance of latently trancscribed varicella-zoster virus genes in human ganglia. J Virol 81:2950–2956PubMedCrossRef
6.
Davison AJ, Scott J (1986) The complete DNA sequence of varicella zoster virus. J Gen Virol 67:1759–1816PubMedCrossRef
7.
Dehbrus S, Sadzot-Delvasax C, Nikkels AF, Piette J, Rentier B (1995) Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol 69:3240–3245
8.
Dohner DE, Adams SG, Gelb LD (1998) Varicella-zoster virus DNA from persistently infected cells contains novel tandem duplications. J Gen Virol 69:2229–2249CrossRef
9.
Faga B, Maury W, Bruckner DA, Grose C (2001) Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome. Virology 280:1–6PubMedCrossRef
10.
Fox RJ, Galetta SL, Mahalingam R, Wellish M, Forghani B, Gilden DH (2001) Acute, chronic, and recurrent varicella zoster virus neuropathy without zoster rash. Neurology 57:351–354PubMed
11.
Garnier J, Gibrat JF, Robson B (1996) GOR method for predicting protein secondary structure from amino acid sequence. Meth Enz 266:540–553CrossRef
12.
Gilden DH, Beinlich BR, Rubinstien EM, Stommel E, Swenson R, Rubinstein D, Mahalingam R (1994) Varicella zoster virus myelitis: an expanding spectrum. Neurology 44:1818–1823PubMed
13.
Hoover SE, Cohrs RJ, Rangel ZG, Gilden DH, Munson P, Cohen JI (2006) Downregulation of varicella-zoster virus (VZV) immediate-early ORF62 transcription by VZV ORF63 correlates with virus replication in vitro and with latency. J Virol 80:3459–3468PubMedCrossRef
14.
Kennedy PG, Grinfeld E, Bell JF (2000) Varicella-zoster virus gene expression in latently infected and explanted human ganglia. J Virol 74:11893–11898PubMedCrossRef
15.
Kennedy PG, Grinfeld E, Bontems S, Sadzot-Delvaux C (2001) Vanicella-zoster virus gene expression in latently infected rat dorsal root ganglia. Virology 289:218–223PubMedCrossRef
16.
Mahalingam R, Wellish M, Cohrs R, Debrus S, Piette J, Rentier B, Gilden DH (1996) Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci USA 93:2122–2124PubMedCrossRef
17.
Meier JL, Holman RP, Croen KD, Smialek JE, Straus SE (1993) Varicella-zoster virus transcription in human trigeminal ganglia. Virology 193:193–200PubMedCrossRef
18.
Mueller NH, Graf LL, Shearer AJ, Owens GP, Gilden DH, Cohrs RJ (2008) Construction of recombinant mouse IgG1 antibody directed against varicella zoster virus immediate early protein 63. Hybridoma 27:1–10PubMedCrossRef
19.
Quinlivan M, Breuer J (2006) Molecular studies of Varicella zoster virus. Rev Med Virol 16:225–250PubMedCrossRef
20.
Sadzot-Delvaux C, Debrus S, Nikkels A, Pielte J, Rentier B (1995) Varicella zoster virus latency in the adult rat is a useful model for human latent infection. Neurulogy 45(12 Suppl 8):S18–S20
21.
Sauerbrei A, Philipps A, Zell R, Wutzler P (2007) Genotyping of varicella-zoster virus strains after serial passages in cell culture. J Virol Methods 145:80–83PubMedCrossRef
22.
Shankar V, Fisher S, Forghani B, Vafai A (2001) Nucleotide sequence analysis of varicella-zoster virus glycoprotein E epitope coding regions. Vaccine 19:3830–3833PubMedCrossRef
23.
Vafai A, Wroblewska Z, Wellish M, Green M, Gilden D (1984) Analysis of three late varicella-zoster virus proteins, a 125,000-molecular-weight protein and gp1 and gp3. J Virol 52:953–959PubMed
24.
Vafai A, Murray RS, Wellish M, Devlin M, Gilden DH (1988) Expression of varicella-zoster virus and herpes simplex virus in normal human trigeminal ganglia. Proc Natl Acad Sci USA 85:2362–2366PubMedCrossRef
25.
Vafai A, Wroblewska Z, Mahalingam R, Cabirac G, Wellish M, Cisco M, Gilden D (1988) Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies. J Virol 62:2544–2551PubMed
26.
Vafai A, Wroblewska Z, Graf L (1990) Antigenic cross-reaction between a varicella-zoster virus nucleocapsid protein encoded by gene 40 and a herpes simplex virus nucleocapsid protein. Virus Res 15:163–174PubMedCrossRef
27.
Washburn MP, Wolters D, Yates JRIII (2001) Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 19:242–247PubMedCrossRef
28.
Wroblewska Z, Gilden D, Green M, Devlin M, Vafai A (1985) Affinity-purified varicella-zoster virus glycoprotein gp1/gp3 stimulates the production of neutralizing antibody. J Gen Virol 66:1795–1799PubMedCrossRef
Metadata
Title
Stability of varicella-zoster virus open reading frame 63
Publication date
01-10-2008
Published in
Archives of Virology / Issue 10/2008
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-008-0197-4

Other articles of this Issue 10/2008

Archives of Virology 10/2008 Go to the issue

Brief Report

EBV and CMV in chronic periodontitis: a prevalence study

Original Article

Mutation spectra of the surface-protein-coding region of the HBV genome in HBV-vaccinated and non-vaccinated individuals in Hungary

Original Article

Biological and molecular characterization of a putative new sobemovirus infecting Imperata cylindrica and maize in Africa

Original Article

High prevalence of hepatitis B virus pre-S mutation and its association with hepatocellular carcinoma in Qidong, China

Annotated Sequence Record

Six novel begomoviruses infecting tomato and associated weeds in Southeastern Brazil

Brief Report

Noroviruses and sapoviruses in pigs in Belgium
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits